Grass pollen allergy vaccine not to be sneezed at

Hay fever makes the summer miserable for so many people, and the possibilities for treatment are daily antihistamines, or allergy shots, low doses of an extract of pollen under the skin for as long as 5 years. Biomay is developing a recombinant grass pollen allergy vaccine, known as BM32, that could cut symptoms after just three doses. The vaccine has just started a Phase II trial in Vienna, where 60 patients will get three doses, and the researchers are looking for a fall in symptoms, as well as indications for the dose for larger clinical trials. This is the first of Biomay's peptide-carrier vaccines, made up of an antigen fused to a carrier peptide, and if the results are positive, the company will use the technology to develop vaccines against other allergies. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.